Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAPTIVATE: DNTH103 in adults with CIDP
ChiCTR2600122401Phase 3Not yet recruiting
- Sponsor
- Huashan Hospital
- Start
- Apr 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of claseprubart in chronic inflammatory demyelinating polyneuropathy (CIDP) (3 arms), sponsored by Huashan Hospital. Primary endpoint: Time from first dose in Part B to relapse as assessed by adjusted INCAT. Planned start Apr 2026; status: not yet recruiting.
02
Drugs
claseprubart
03
Conditions
chronic inflammatory demyelinating polyneuropathy (CIDP)
Beyond the preview
Go deeper on ChiCTR2600122401.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600122401.